메뉴 건너뛰기




Volumn 4, Issue 5, 2008, Pages 991-1000

Update on the clinical utility of fenofibrate in mixed dyslipidemias: Mechanisms of action and rational prescribing

Author keywords

Fenofibrate; HDL cholesterol; LDL cholesterol; Mixed dyslipidemia; Triglycerides

Indexed keywords

BILE ACID SEQUESTRANT; CERIVASTATIN; COLESEVELAM; COUMARIN; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

EID: 56849101891     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (56)

References (96)
  • 1
    • 0030690553 scopus 로고    scopus 로고
    • Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
    • Adkins JC, Faulds D. 1997. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 54:615-33.
    • (1997) Drugs , vol.54 , pp. 615-633
    • Adkins, J.C.1    Faulds, D.2
  • 3
    • 14844292088 scopus 로고    scopus 로고
    • Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)
    • Ansquer JC, Foucher C, Rattier S, et al. 2005. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis, 45:485-93.
    • (2005) Am J Kidney Dis , vol.45 , pp. 485-493
    • Ansquer, J.C.1    Foucher, C.2    Rattier, S.3
  • 4
    • 0036636769 scopus 로고    scopus 로고
    • Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia
    • Athyros VG, Papageorgiou AA, Athyrou VV, et al. 2002. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care, 25:1198-202.
    • (2002) Diabetes Care , vol.25 , pp. 1198-1202
    • Athyros, V.G.1    Papageorgiou, A.A.2    Athyrou, V.V.3
  • 5
    • 34447520136 scopus 로고    scopus 로고
    • Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
    • Bansal S, Buring JE, Rifai N, et al. 2007. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 298:309-16.
    • (2007) JAMA , vol.298 , pp. 309-316
    • Bansal, S.1    Buring, J.E.2    Rifai, N.3
  • 6
    • 34748887666 scopus 로고    scopus 로고
    • HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    • Barter P, Gotto AM, La Rosa JC, et al. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 357:1301-10.
    • (2007) N Engl J Med , vol.357 , pp. 1301-1310
    • Barter, P.1    Gotto, A.M.2    La Rosa, J.C.3
  • 7
    • 37549041988 scopus 로고    scopus 로고
    • Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    • Barter PJ, Rye KA. 2008. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol, 28:39-46.
    • (2008) Arterioscler Thromb Vasc Biol , vol.28 , pp. 39-46
    • Barter, P.J.1    Rye, K.A.2
  • 8
    • 4143071323 scopus 로고    scopus 로고
    • Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans
    • Bergman AJ, Murphy G, Burke J, et al. 2004. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol, 44:1054-62.
    • (2004) J Clin Pharmacol , vol.44 , pp. 1054-1062
    • Bergman, A.J.1    Murphy, G.2    Burke, J.3
  • 9
    • 0034077628 scopus 로고    scopus 로고
    • Diabetic dyslipidemia. Current treatment recommendations
    • Best JD, O'Neal DN. 2000. Diabetic dyslipidemia. Current treatment recommendations. Drugs, 59:1101-11.
    • (2000) Drugs , vol.59 , pp. 1101-1111
    • Best, J.D.1    O'Neal, D.N.2
  • 10
    • 11844296800 scopus 로고    scopus 로고
    • Efficacy and safety of high-density lipoprotein cholesterol-increasing coumpounds: A meta-analysis of randomized controlled trials
    • Birjmohun RS, Hutten BA, Kastelein JJP, et al. 2005. Efficacy and safety of high-density lipoprotein cholesterol-increasing coumpounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol, 45:185-97.
    • (2005) J Am Coll Cardiol , vol.45 , pp. 185-197
    • Birjmohun, R.S.1    Hutten, B.A.2    Kastelein, J.J.P.3
  • 11
    • 39649114249 scopus 로고    scopus 로고
    • on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    • Burgess D, Hunt D, Li L, et al. 2007. on behalf of the FIELD Investigators. Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Circulation, 116(Suppl II):838.
    • (2007) Circulation , vol.116 , Issue.SUPPL. II , pp. 838
    • Burgess, D.1    Hunt, D.2    Li, L.3
  • 12
    • 33846083971 scopus 로고    scopus 로고
    • Buse JB, Ginsberg HN, Bakris GL, et al. 2007. for the American Heart Association and the American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115:114-26.
    • Buse JB, Ginsberg HN, Bakris GL, et al. 2007. for the American Heart Association and the American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 115:114-26.
  • 13
    • 33746355566 scopus 로고    scopus 로고
    • Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
    • Cannon CP, Steinberg BA, Murphy SA, et al. 2006. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol, 48:438-45.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 438-445
    • Cannon, C.P.1    Steinberg, B.A.2    Murphy, S.A.3
  • 14
    • 0037324362 scopus 로고    scopus 로고
    • Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia
    • Capell WH, De Souza CA, Poirier P, et al. 2003. Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia. Arterioscler Thromb Vasc Biol, 23:307-13.
    • (2003) Arterioscler Thromb Vasc Biol , vol.23 , pp. 307-313
    • Capell, W.H.1    De Souza, C.A.2    Poirier, P.3
  • 15
    • 3042623891 scopus 로고    scopus 로고
    • Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy
    • Chang JT, Staffa JA, Parks M, et al. 2004. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Safety, 13:417-26.
    • (2004) Pharmacoepidemiol Drug Safety , vol.13 , pp. 417-426
    • Chang, J.T.1    Staffa, J.A.2    Parks, M.3
  • 16
    • 33644784875 scopus 로고    scopus 로고
    • Fibrates: Therapeutic review
    • Chapman MJ. 2006. Fibrates: therapeutic review. Br J Diabetes Vasc Dis, 6:11-8.
    • (2006) Br J Diabetes Vasc Dis , vol.6 , pp. 11-18
    • Chapman, M.J.1
  • 17
    • 0035138625 scopus 로고    scopus 로고
    • PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
    • Chinetti G, Lestavel S, Bocher V, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med, 7:53-8.
    • (2001) Nat Med , vol.7 , pp. 53-58
    • Chinetti, G.1    Lestavel, S.2    Bocher, V.3
  • 18
    • 85183084678 scopus 로고    scopus 로고
    • Cholesterol Treatment Trialist's (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet, 366:1267-78.
    • Cholesterol Treatment Trialist's (CTT) Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet, 366:1267-78.
  • 19
    • 27744605739 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between statins and fibrates
    • Corsini A, Bellosta S, Davidson MH. 2005. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol, 96(Suppl):44K-49K.
    • (2005) Am J Cardiol , vol.96 , Issue.SUPPL.
    • Corsini, A.1    Bellosta, S.2    Davidson, M.H.3
  • 20
    • 0034912018 scopus 로고    scopus 로고
    • Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality
    • Cui Y, Blumenthal RS, Flaws JA, et al. 2001. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med, 161:1413-9.
    • (2001) Arch Intern Med , vol.161 , pp. 1413-1419
    • Cui, Y.1    Blumenthal, R.S.2    Flaws, J.A.3
  • 22
    • 0035941990 scopus 로고    scopus 로고
    • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study
    • Diabetes Atherosclerosis Intervention Study Investigators
    • [DAIS] Diabetes Atherosclerosis Intervention Study Investigators. 2001. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study. Lancet, 357:905-10.
    • (2001) Lancet , vol.357 , pp. 905-910
  • 23
    • 0037278367 scopus 로고    scopus 로고
    • Fenofibrate-induced hyperhomocysteinaemia. Clinical implications and management
    • Dierkes J, Westphal S, Luley C. 2003. Fenofibrate-induced hyperhomocysteinaemia. Clinical implications and management. Drug Safety, 26:81-91.
    • (2003) Drug Safety , vol.26 , pp. 81-91
    • Dierkes, J.1    Westphal, S.2    Luley, C.3
  • 24
    • 0042329251 scopus 로고    scopus 로고
    • Dyslipidaemia
    • Durrington, P. 2003. Dyslipidaemia. Lancet, 362:717-31.
    • (2003) Lancet , vol.362 , pp. 717-731
    • Durrington, P.1
  • 25
    • 1842559795 scopus 로고    scopus 로고
    • Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia
    • Durrington PN, Tuomiletho J, Hamann A, et al. 2004. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diab Res Clin Pract, 64:137-51.
    • (2004) Diab Res Clin Pract , vol.64 , pp. 137-151
    • Durrington, P.N.1    Tuomiletho, J.2    Hamann, A.3
  • 26
    • 0032568095 scopus 로고    scopus 로고
    • Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
    • Ellen RLB, McPherson R. 1998. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol, 81(4A):60B-65B.
    • (1998) Am J Cardiol , vol.81 , Issue.4 A
    • Ellen, R.L.B.1    McPherson, R.2
  • 27
    • 56849099877 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: full text. 2007. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil, 14(Suppl 2): S1-S113.
    • European guidelines on cardiovascular disease prevention in clinical practice: full text. 2007. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil, 14(Suppl 2): S1-S113.
  • 28
    • 0038236574 scopus 로고    scopus 로고
    • Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. A critical review of potential benefits and drawbacks
    • Farnier M. 2003. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative. A critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs, 3:169-78.
    • (2003) Am J Cardiovasc Drugs , vol.3 , pp. 169-178
    • Farnier, M.1
  • 29
    • 34250837432 scopus 로고    scopus 로고
    • Ezetimibe plus fenofibrate: A new combination therapy for the management of mixed hyperlipidaemia?
    • Farnier M. 2007. Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia? Expert Opin Pharmacother, 8:1345-52.
    • (2007) Expert Opin Pharmacother , vol.8 , pp. 1345-1352
    • Farnier, M.1
  • 30
    • 0033985113 scopus 로고    scopus 로고
    • Farnier M, Dejager S; and the French Fluvastatin Study Group. 2000. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol, 85:53-7.
    • Farnier M, Dejager S; and the French Fluvastatin Study Group. 2000. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. Am J Cardiol, 85:53-7.
  • 31
    • 18744365508 scopus 로고    scopus 로고
    • Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
    • Farnier M, Freeman MW, Macdonnel G, et al. 2005. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J, 26:897-905.
    • (2005) Eur Heart J , vol.26 , pp. 897-905
    • Farnier, M.1    Freeman, M.W.2    Macdonnel, G.3
  • 32
    • 33846199963 scopus 로고    scopus 로고
    • Farnier M, Roth E, Gil-Extremera B, et al; for the Ezetimibe/Simvastatin + Fenofibrate Study Group. 2007. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J, 153:335e1-335e8.
    • Farnier M, Roth E, Gil-Extremera B, et al; for the Ezetimibe/Simvastatin + Fenofibrate Study Group. 2007. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J, 153:335e1-335e8.
  • 33
    • 5144227019 scopus 로고    scopus 로고
    • The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
    • Fazio S, Linton McRF. 2004. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscl Rep, 6:148-57.
    • (2004) Curr Atheroscl Rep , vol.6 , pp. 148-157
    • Fazio, S.1    Linton, M.R.F.2
  • 34
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med, 317:1237-45.
    • (1987) N Engl J Med , vol.317 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3
  • 35
    • 33645076793 scopus 로고    scopus 로고
    • Mode of action of fibrates in the regulation of triglycerides and HDL-cholesterol metabolism
    • Fruchart JC, Duriez P. 2006. Mode of action of fibrates in the regulation of triglycerides and HDL-cholesterol metabolism. Drugs Today, 42:39-64.
    • (2006) Drugs Today , vol.42 , pp. 39-64
    • Fruchart, J.C.1    Duriez, P.2
  • 37
    • 1842477680 scopus 로고    scopus 로고
    • Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus
    • Genest J, Frohlich J, Steiner G. 2004. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol, 93:848-53.
    • (2004) Am J Cardiol , vol.93 , pp. 848-853
    • Genest, J.1    Frohlich, J.2    Steiner, G.3
  • 38
    • 34250753275 scopus 로고    scopus 로고
    • Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
    • Ginsberg HN, Bonds DE, Lovato LC, et al. 2007. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol, 99(Suppl):56i-67i.
    • (2007) Am J Cardiol , vol.99 , Issue.SUPPL.
    • Ginsberg, H.N.1    Bonds, D.E.2    Lovato, L.C.3
  • 39
    • 0017384270 scopus 로고
    • High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
    • Gordon T, Castelli WP, Hjortland MC, et al. 1977. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 62:707-14.
    • (1977) Am J Med , vol.62 , pp. 707-714
    • Gordon, T.1    Castelli, W.P.2    Hjortland, M.C.3
  • 40
    • 0024501678 scopus 로고
    • High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
    • Gordon DJ, Probstfield JL, Garrison RJ, et al. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79:8-15.
    • (1989) Circulation , vol.79 , pp. 8-15
    • Gordon, D.J.1    Probstfield, J.L.2    Garrison, R.J.3
  • 41
    • 9644252909 scopus 로고    scopus 로고
    • Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
    • Graham DJ, Staffa JA, Shatin D, et al. 2004. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA, 292:2585-90.
    • (2004) JAMA , vol.292 , pp. 2585-2590
    • Graham, D.J.1    Staffa, J.A.2    Shatin, D.3
  • 42
    • 3142729178 scopus 로고    scopus 로고
    • Grundy SM, Cleeman JI, Merz CNB, et al. 2004a. for the Coordinating Committee of the National Cholesterol Education Program. Implications or recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110:227-39.
    • Grundy SM, Cleeman JI, Merz CNB, et al. 2004a. for the Coordinating Committee of the National Cholesterol Education Program. Implications or recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110:227-39.
  • 43
    • 0842285784 scopus 로고    scopus 로고
    • Grundy SM, Hansen B, Smith SC Jr et al. 2004b. for the American Heart Association, the National Heart, Lung, and Blood Institute, and The American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation, 109:551-6.
    • Grundy SM, Hansen B, Smith SC Jr et al. 2004b. for the American Heart Association, the National Heart, Lung, and Blood Institute, and The American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation, 109:551-6.
  • 44
    • 13844272245 scopus 로고    scopus 로고
    • Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
    • Grundy SM, Vega GL, Yuan Z, et al. 2005. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol, 95:462-8.
    • (2005) Am J Cardiol , vol.95 , pp. 462-468
    • Grundy, S.M.1    Vega, G.L.2    Yuan, Z.3
  • 45
    • 0029941224 scopus 로고    scopus 로고
    • Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia
    • Guerin M, Bruckert E, Dolphin PJ, et al. 1996. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic dense LDL profile in combined hyperlipidemia. Arterioscler Thromb Vasc Biol, 16:763-72.
    • (1996) Arterioscler Thromb Vasc Biol , vol.16 , pp. 763-772
    • Guerin, M.1    Bruckert, E.2    Dolphin, P.J.3
  • 46
    • 23044464472 scopus 로고    scopus 로고
    • The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite
    • Gustavson LE, Schweitzer SM, Koehne-Voss S, et al. 2005. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol, 45:947-53.
    • (2005) J Clin Pharmacol , vol.45 , pp. 947-953
    • Gustavson, L.E.1    Schweitzer, S.M.2    Koehne-Voss, S.3
  • 47
    • 0036364909 scopus 로고    scopus 로고
    • Fenofibrate increases creatinemia by increasing metabolic production of creatinine
    • Hottelart C, El Esper N, Rose F, et al. 2002. Fenofibrate increases creatinemia by increasing metabolic production of creatinine. Nephron, 92:536-41.
    • (2002) Nephron , vol.92 , pp. 536-541
    • Hottelart, C.1    El Esper, N.2    Rose, F.3
  • 48
    • 11144239674 scopus 로고    scopus 로고
    • Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
    • Jones PH, Davidson MH. 2005. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol, 95:120-2.
    • (2005) Am J Cardiol , vol.95 , pp. 120-122
    • Jones, P.H.1    Davidson, M.H.2
  • 49
    • 0036094162 scopus 로고    scopus 로고
    • Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modification by fibric acid
    • Kaneko T, Fuji S, Matsumoto A, et al. 2002. Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modification by fibric acid. Arterioscler Thromb Vasc Biol, 22:855-60.
    • (2002) Arterioscler Thromb Vasc Biol , vol.22 , pp. 855-860
    • Kaneko, T.1    Fuji, S.2    Matsumoto, A.3
  • 50
    • 46449096115 scopus 로고    scopus 로고
    • Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    • Kastelein JJP, van der Steeg WA, Holme I, et al. 2008. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation, 117:3002-9.
    • (2008) Circulation , vol.117 , pp. 3002-3009
    • Kastelein, J.J.P.1    van der Steeg, W.A.2    Holme, I.3
  • 51
    • 33846262603 scopus 로고    scopus 로고
    • Fenofibrate. A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus
    • Keating GM, Croom KF. 2007. Fenofibrate. A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs, 67:121-53.
    • (2007) Drugs , vol.67 , pp. 121-153
    • Keating, G.M.1    Croom, K.F.2
  • 52
    • 0036382889 scopus 로고    scopus 로고
    • Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia
    • Keating GM, Ormrod D. 2002. Micronised fenofibrate. An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 62:1909-44.
    • (2002) Drugs , vol.62 , pp. 1909-1944
    • Keating, G.M.1    Ormrod, D.2
  • 54
    • 19944379835 scopus 로고    scopus 로고
    • Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adinopectin levels in patients with primary hypertriglyceridemia
    • Koh KK, Han SH, Quon MJ, et al. 2005. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adinopectin levels in patients with primary hypertriglyceridemia. Diabetes Care, 28:1419-24.
    • (2005) Diabetes Care , vol.28 , pp. 1419-1424
    • Koh, K.K.1    Han, S.H.2    Quon, M.J.3
  • 56
    • 34447523594 scopus 로고    scopus 로고
    • Triglycerides and risk for coronary heart disease
    • McBride PE. 2007. Triglycerides and risk for coronary heart disease. JAMA, 298:336-8.
    • (2007) JAMA , vol.298 , pp. 336-338
    • McBride, P.E.1
  • 57
    • 33646035503 scopus 로고    scopus 로고
    • Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipiderma
    • McKenney JM, Farnier M, Lo KW, et al. 2006. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipiderma. J Am Coll Cardiol, 47:1584-7.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 1584-1587
    • McKenney, J.M.1    Farnier, M.2    Lo, K.W.3
  • 58
    • 25444497513 scopus 로고    scopus 로고
    • Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia
    • McKenney J, Jones M, Abby S. 2005. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin, 21:1403-12.
    • (2005) Curr Med Res Opin , vol.21 , pp. 1403-1412
    • McKenney, J.1    Jones, M.2    Abby, S.3
  • 59
    • 0036147354 scopus 로고    scopus 로고
    • A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration
    • Maison P, Mennen L, Sapinho D, et al. 2002. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis, 160:155-60.
    • (2002) Atherosclerosis , vol.160 , pp. 155-160
    • Maison, P.1    Mennen, L.2    Sapinho, D.3
  • 60
    • 0037424494 scopus 로고    scopus 로고
    • Fibrates down-regulate hepatic scavenger receptor class B type 1 protein expression in mice
    • Mardones P, Pilon A, Bouly M, et al. 2003. Fibrates down-regulate hepatic scavenger receptor class B type 1 protein expression in mice. J Biol Chem, 278:7884-90.
    • (2003) J Biol Chem , vol.278 , pp. 7884-7890
    • Mardones, P.1    Pilon, A.2    Bouly, M.3
  • 61
    • 0037292311 scopus 로고    scopus 로고
    • An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers
    • Martin PD, Dane AL, Shneck DW, et al. 2003. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther, 25:459-71.
    • (2003) Clin Ther , vol.25 , pp. 459-471
    • Martin, P.D.1    Dane, A.L.2    Shneck, D.W.3
  • 62
    • 38849179382 scopus 로고    scopus 로고
    • Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)
    • May HT, Anderson JL, Pearson RR, et al. 2008. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol, 101:486-9.
    • (2008) Am J Cardiol , vol.101 , pp. 486-489
    • May, H.T.1    Anderson, J.L.2    Pearson, R.R.3
  • 63
    • 33645282568 scopus 로고    scopus 로고
    • Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease
    • Mikael LG, Genest J Jr, Rozen R. 2006. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res, 98:564-71.
    • (2006) Circ Res , vol.98 , pp. 564-571
    • Mikael, L.G.1    Genest Jr, J.2    Rozen, R.3
  • 64
    • 38949171001 scopus 로고    scopus 로고
    • Miller M, Cannon CP, Murphy SA, et al. 2008. for the PROVE IT-TIMI 22 Investigators. Impact of triglycerides levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 51:724-30.
    • Miller M, Cannon CP, Murphy SA, et al. 2008. for the PROVE IT-TIMI 22 Investigators. Impact of triglycerides levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 51:724-30.
  • 65
    • 33745685394 scopus 로고    scopus 로고
    • The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study
    • Muhlestein JB, May HT, Jensen FR, et al. 2006. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol, 48:396-401.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 396-401
    • Muhlestein, J.B.1    May, H.T.2    Jensen, F.R.3
  • 66
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. JAMA, 285:2486-97.
    • [NCEP] Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. JAMA, 285:2486-97.
  • 67
    • 10744225301 scopus 로고    scopus 로고
    • Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA, 291:1071-80.
    • (2004) JAMA , vol.291 , pp. 1071-1080
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 68
    • 34447511196 scopus 로고    scopus 로고
    • Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
    • Nordestgaard BG, Benn M, Schnohr P, et al. 2007. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 298:299-308.
    • (2007) JAMA , vol.298 , pp. 299-308
    • Nordestgaard, B.G.1    Benn, M.2    Schnohr, P.3
  • 69
    • 0034145932 scopus 로고    scopus 로고
    • Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers
    • Pan WJ, Gustavson LE, Achari R, et al. 2000. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol, 40:316-23.
    • (2000) J Clin Pharmacol , vol.40 , pp. 316-323
    • Pan, W.J.1    Gustavson, L.E.2    Achari, R.3
  • 70
    • 43049118952 scopus 로고    scopus 로고
    • Cross-talk between statins and PPARα in cardiovascular diseases: Clinical evidence and basic mechanisms
    • Paumelle R, Staels B. 2008. Cross-talk between statins and PPARα in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med, 18:73-8.
    • (2008) Trends Cardiovasc Med , vol.18 , pp. 73-78
    • Paumelle, R.1    Staels, B.2
  • 71
    • 0036890093 scopus 로고    scopus 로고
    • Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus
    • Playford DA, Watts GF, Best JD, et al. 2002. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol, 90:1254-7.
    • (2002) Am J Cardiol , vol.90 , pp. 1254-1257
    • Playford, D.A.1    Watts, G.F.2    Best, J.D.3
  • 72
    • 0036233667 scopus 로고    scopus 로고
    • Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization
    • Prueksaritanont T, Subramanian R, Fang X, et al. 2002b. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos, 30:505-12.
    • (2002) Drug Metab Dispos , vol.30 , pp. 505-512
    • Prueksaritanont, T.1    Subramanian, R.2    Fang, X.3
  • 73
    • 0036843479 scopus 로고    scopus 로고
    • Effects of fibrates on metabolism of statins in human hepatocytes
    • Prueksaritanont T, Tang C, Qiu Y, et al. 2002a. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos, 30:1280-7.
    • (2002) Drug Metab Dispos , vol.30 , pp. 1280-1287
    • Prueksaritanont, T.1    Tang, C.2    Qiu, Y.3
  • 74
    • 22244446183 scopus 로고    scopus 로고
    • Non-HDL-cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women
    • Ridker PM, Rifai N, Cook NR, et al. 2005. Non-HDL-cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA, 294:326-33.
    • (2005) JAMA , vol.294 , pp. 326-333
    • Ridker, P.M.1    Rifai, N.2    Cook, N.R.3
  • 75
    • 85136452889 scopus 로고    scopus 로고
    • Robins SJ, Collins D, Wittes JT, et al. 2001. for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: a randomized controlled trial. JAMA, 285:1585-91.
    • Robins SJ, Collins D, Wittes JT, et al. 2001. for the VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: a randomized controlled trial. JAMA, 285:1585-91.
  • 76
    • 43949097868 scopus 로고    scopus 로고
    • Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
    • Rosenson RS, Kuskin AL, Wolff DA, et al. 2008. Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis, 198:381-8.
    • (2008) Atherosclerosis , vol.198 , pp. 381-388
    • Rosenson, R.S.1    Kuskin, A.L.2    Wolff, D.A.3
  • 77
    • 0037049366 scopus 로고    scopus 로고
    • Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)
    • Rubins HB, Robins SJ, Collins D, et al. 2002. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 162:2597-604.
    • (2002) Arch Intern Med , vol.162 , pp. 2597-2604
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 78
    • 33846637379 scopus 로고    scopus 로고
    • Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies
    • Sarwar N, Danesh J, Eiriksdottir G, et al. 2007. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation, 115:450-8.
    • (2007) Circulation , vol.115 , pp. 450-458
    • Sarwar, N.1    Danesh, J.2    Eiriksdottir, G.3
  • 79
    • 56349137734 scopus 로고    scopus 로고
    • on behalf of the FIELD Investigators. Features of metabolic syndrome indentify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate
    • Scott R, d'Emden M, Best J, et al. 2007. on behalf of the FIELD Investigators. Features of metabolic syndrome indentify individuals with type 2 diabetes mellitus at high risk for cardiovascular events and greater absolute benefits of fenofibrate. Circulation, 116(Suppl II):838.
    • (2007) Circulation , vol.116 , Issue.SUPPL. II , pp. 838
    • Scott, R.1    d'Emden, M.2    Best, J.3
  • 80
    • 0034924212 scopus 로고    scopus 로고
    • Statin-fibrate combination therapy
    • Shek A, Ferrill MJ. 2001. Statin-fibrate combination therapy. Ann Pharmacother, 35:908-17.
    • (2001) Ann Pharmacother , vol.35 , pp. 908-917
    • Shek, A.1    Ferrill, M.J.2
  • 81
    • 0032506273 scopus 로고    scopus 로고
    • Mechanism of action of fibrates on lipid and lipoprotein metabolism
    • Staels B, Dallongeville J, Auwerx J, et al. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 98:2088-93.
    • (1998) Circulation , vol.98 , pp. 2088-2093
    • Staels, B.1    Dallongeville, J.2    Auwerx, J.3
  • 82
    • 4344675397 scopus 로고    scopus 로고
    • Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia
    • Stefanutti C, Bucci A, Di Giacomo S, et al. 2004. Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia. Clin Drug Invest, 24:465-77.
    • (2004) Clin Drug Invest , vol.24 , pp. 465-477
    • Stefanutti, C.1    Bucci, A.2    Di Giacomo, S.3
  • 83
    • 23744444361 scopus 로고    scopus 로고
    • Recent National Cholesterol Education Program Adult Treatment Panel III update: Adjustments and options
    • Stone NJ, Bilek S, Rosenbaum S. 2005. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol, 96:53E-59E.
    • (2005) Am J Cardiol , vol.96
    • Stone, N.J.1    Bilek, S.2    Rosenbaum, S.3
  • 84
    • 0842346182 scopus 로고    scopus 로고
    • Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis
    • Syvanne M, Whittall RA, Turpeinen U, et al. 2004. Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis. Atherosclerosis, 172:267-72.
    • (2004) Atherosclerosis , vol.172 , pp. 267-272
    • Syvanne, M.1    Whittall, R.A.2    Turpeinen, U.3
  • 85
    • 4143058119 scopus 로고    scopus 로고
    • The triglyceride-high density lipoprotein axis: An important target of therapy?
    • Szapary PO, Rader DJ. 2004. The triglyceride-high density lipoprotein axis: an important target of therapy? Am Heart J, 148:211-21.
    • (2004) Am Heart J , vol.148 , pp. 211-221
    • Szapary, P.O.1    Rader, D.J.2
  • 86
    • 34250785602 scopus 로고    scopus 로고
    • Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods
    • The ACCORD Study Group
    • The ACCORD Study Group. 2007. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol, 99 (Suppl):21i-33i.
    • (2007) Am J Cardiol , vol.99 , Issue.SUPPL.
  • 87
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study):randomised controlled trial
    • The FIELD study investigators
    • The FIELD study investigators. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study):randomised controlled trial. Lancet, 366:1849-61.
    • (2005) Lancet , vol.366 , pp. 1849-1861
  • 88
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary
    • The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes EASD
    • The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J, 28:88-136.
    • (2007) Eur Heart J , vol.28 , pp. 88-136
  • 89
    • 43849104295 scopus 로고    scopus 로고
    • Effects of fenofibrate and ezetunibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
    • Tribble DL, Farnier M, Macdonell G, et al. 2008. Effects of fenofibrate and ezetunibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metab Clin Experim, 57:796-801.
    • (2008) Metab Clin Experim , vol.57 , pp. 796-801
    • Tribble, D.L.1    Farnier, M.2    Macdonell, G.3
  • 91
    • 27844603359 scopus 로고    scopus 로고
    • Homocysteine and thrombosis: From basic science to clinical evidence
    • Undas A, Brozek J, Szczeklik A. 2005. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost, 94:907-15.
    • (2005) Thromb Haemost , vol.94 , pp. 907-915
    • Undas, A.1    Brozek, J.2    Szczeklik, A.3
  • 92
    • 0037426396 scopus 로고    scopus 로고
    • Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: The Diabetes Atherosclerosis Intervention Study (DAIS)
    • Vakkilainen J, Steiner G, Ansquer JC, et al. 2003. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation, 107:1733-7.
    • (2003) Circulation , vol.107 , pp. 1733-1737
    • Vakkilainen, J.1    Steiner, G.2    Ansquer, J.C.3
  • 93
    • 0037446467 scopus 로고    scopus 로고
    • Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome
    • Vega GL, Ma PTS, Cater NB, et al. 2003. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol, 91:956-60.
    • (2003) Am J Cardiol , vol.91 , pp. 956-960
    • Vega, G.L.1    Ma, P.T.S.2    Cater, N.B.3
  • 94
    • 0013301537 scopus 로고    scopus 로고
    • Statin-fibrate combination therapy for hyperlipidaemia: A review
    • Wierzbicki AS, Mikhailidis DP, Wray R, et al. 2003. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin, 19:1-14.
    • (2003) Curr Med Res Opin , vol.19 , pp. 1-14
    • Wierzbicki, A.S.1    Mikhailidis, D.P.2    Wray, R.3
  • 95
    • 56849115407 scopus 로고    scopus 로고
    • World Health Statistics
    • World Health Statistics. 2008. www.who.int/whosis
    • (2008)
  • 96
    • 33646440029 scopus 로고    scopus 로고
    • Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: Clinical and experimental evidence
    • Zambon A, Gervois P, Pauletto P, et al. 2006. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol, 26:977-86.
    • (2006) Arterioscler Thromb Vasc Biol , vol.26 , pp. 977-986
    • Zambon, A.1    Gervois, P.2    Pauletto, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.